PLX4032, also known as vemurafenib, is an inhibitor that binds to the ATP-binding site of mutated BRAF kinase, inhibiting ERK signaling only in tumor cells expressing BRAFV600E mutations [60]. This evidence concerns the gene BRAF and neoplasm.